Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
about
A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusEmerging utility of once-weekly exenatide in patients with type 2 diabetesExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectivesLipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?Update on the treatment of type 2 diabetes mellitusExenatide once weekly: opportunities in the primary care setting.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 DiabetesComparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsInjection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting SystemExenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulationsComparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.Exenatide extended-release; clinical trials, patient preference, and economic considerations.Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.Evolution of exenatide as a diabetes therapeutic.Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion.Long-acting preparations of exenatideReview of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.Population pharmacokinetics of exenatideExenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production.Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.Exenatide extended-release: a review of its use in type 2 diabetes mellitus.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.Advances in pharmacologic therapies for type 2 diabetes.Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.Once weekly exenatide: efficacy, tolerability and place in therapy.Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetesInjectable controlled release depots for large molecules.
P2860
Q26765155-567E2CCE-E1CB-42B7-B77F-770E0A8CB8FAQ26777320-F9DFB578-034C-4324-AF95-3502D3744D90Q26797236-CF964C4C-DB89-4761-B6F7-4E7DB675FA6EQ28072729-49987CEF-D266-46D8-BAD8-E0D78ED78019Q28073342-F6FE92B9-F06E-4BC8-BBCD-2A61801F075EQ30431639-97F50E95-AB4A-4D7F-8DCD-08A0D95A9EF4Q33824522-46F9A774-6569-4B2C-ABA7-FE046E327CEAQ33835897-820B9D7A-2AA2-4871-933C-78F3BF2F4A7DQ34512289-05030060-C869-4374-BB8C-6939C2DE2C7BQ34547492-0A7BA6AD-22A8-45B8-8A14-D5FF95947D6BQ35200252-78690751-8A93-4ED1-83EA-786BD8C88DE8Q35654002-49B8DC58-A882-44A5-A39D-8557BDDC3ADDQ35684362-E528D52C-01C1-4075-99BB-951E120F6422Q35910737-E30C484C-EEF4-41D0-B144-D1BC384895F1Q35918380-26727A52-3995-4313-9F84-243F2B0D5644Q36073461-1087EF56-81B1-4DF8-9874-944F630401C0Q36285731-BBFB156B-DC47-432C-9ADC-6128378C319AQ36424233-6CD8981B-12E1-4375-95E7-439536301D4FQ36498695-3C026218-2551-43F0-ABDF-EEC110110079Q36538817-C86E4781-ED2D-4505-A743-BC7C58327972Q36755470-4ED972B6-F547-4CA9-9607-8D7B67F66672Q36877205-2B8ADE0A-5D1C-4597-9845-36FF73933549Q37006853-B305CD41-C97A-43CC-B49D-EF1DFC85E246Q37167742-8ADDEB79-2EA5-4403-B4D8-3F8D7B66472DQ37340223-16D67675-D461-4FAB-B0FE-BE00BF7D99AEQ37410215-DD592061-6520-49D4-A949-C6AB1A047962Q37639905-99CA0639-EA3C-4986-A0A2-A79D417A8834Q37686091-028CB617-4627-4543-8FD4-559BF933A993Q37690751-97D13AD6-AA01-471E-B2EE-9CD54E376342Q38020941-F71047C6-F53D-4A87-82F3-24F6F4F7E71AQ38032321-7718883A-C7AC-4EBC-AFBD-76E19D13EDDCQ38066566-E7403D58-59C1-43B6-8DD9-632F0C44B133Q38069507-8406E69C-1625-4095-9978-823074B4ACD2Q38072616-804DE63C-5181-46BC-9E60-41EA15263114Q38083047-0B983562-4716-46BD-A873-10269BA54D7EQ38083112-D57A9CE8-4528-46F7-8E76-377E6D1DC390Q38095813-23FCE6DC-5021-482B-AC99-F088CDA21CA1Q38167016-CA612D54-B0F5-470D-BD0D-FBE2154EAADBQ38188871-B25B38D9-A809-415E-8FF4-4D52332BC082Q38220192-92DE93D8-C656-4D42-A440-950A256BC64A
P2860
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@en
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@nl
type
label
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@en
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@nl
prefLabel
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@en
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@nl
P2093
P2860
P356
P1476
Encapsulation of exenatide in ...... rmulation for type 2 diabetes.
@en
P2093
Leigh MacConell
Mary Beth DeYoung
Michael Trautmann
Paul Herbert
Viren Sarin
P2860
P304
P356
10.1089/DIA.2011.0050
P577
2011-07-13T00:00:00Z